Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 1989 Apr;96(4):977-85.
doi: 10.1111/j.1476-5381.1989.tb11910.x.

A comparison of the effects of a series of anti-anginal agents in a novel canine model of transient myocardial ischaemia

Affiliations
Comparative Study

A comparison of the effects of a series of anti-anginal agents in a novel canine model of transient myocardial ischaemia

M C Allely et al. Br J Pharmacol. 1989 Apr.

Abstract

1. An anaesthetized canine model of transient myocardial ischemia (TMI) has been developed in which reproducible and reversible electrocardiographic (ECG) and haemodynamic responses are exacerbated by electrical pacing. 2. The model could separate the ECG and haemodynamic effects of compounds with anti-ischaemic properties. 3. Compounds known to possess peripheral or coronary vasodilator properties did not necessarily alleviate the ECG consequences of TMI since glyceryl trinitrate was active whereas dipyridamole was not. The effects of verapamil were complicated by its adverse conduction effects while lidoflazine inhibited the ECG changes only during the ischaemic phase and the 'metabolic modulator' oxfenicine worsened the ECG response. 4. In a model considered to lack coronary reserve, improvements observed in the ischaemic ECG and global ventricular function were considered to result from a direct myocardial effect of the drugs examined rather than by a vascular influence. This was provided to the greatest degree by the Ca2+-entry blockers nifedipine and nicardipine, with flunarizine adopting an intermediate position.

PubMed Disclaimer

References

    1. J Pharmacol Exp Ther. 1966 May;152(2):265-74 - PubMed
    1. Br J Pharmacol. 1988 Feb;93(2):375-82 - PubMed
    1. Curr Ther Res Clin Exp. 1972 Aug;14(8):483-95 - PubMed
    1. Circ Res. 1973 Oct;33(4):445-53 - PubMed
    1. J Pharmacol Exp Ther. 1976 Jan;196(1):15-28 - PubMed

Publication types

Substances

LinkOut - more resources